Table 3.
Association between levels of suicidal ideation from week-2-to-week-8 in repeated-measures mixed model analyses based on early changes in irritability and overall depression.
| β* | SE | F value | df | p value | |
|---|---|---|---|---|---|
| CO-MED | |||||
| Baseline suicidal ideation | 0.17 | 0.01 | 251.98 | 1, 539 | <0.0001 |
| Baseline irritability | 0.03 | 0.03 | 1.02 | 1, 542 | 0.31 |
| Baseline overall depression | 0.10 | 0.03 | 8.85 | 1, 546 | 0.003 |
| Baseline-to-week-2 change in irritability | −0.08 | 0.03 | 5.19 | 1, 534 | 0.023 |
| Baseline-to-week-2 change in overall depression | −0.13 | 0.03 | 15.07 | 1, 548 | 0.0001 |
| EMBARC | |||||
| Baseline suicidal ideation | 0.30 | 0.05 | 36.18 | 1, 216 | <0.0001 |
| Baseline irritability | 0.41 | 0.06 | 50.85 | 1, 216 | <0.0001 |
| Baseline overall depression | 0.02 | 0.05 | 0.11 | 1, 216 | 0.74 |
| Baseline-to-week-2 change in irritability | −0.50 | 0.05 | 85.87 | 1, 214 | <0.0001 |
| Baseline-to-week-2 change in overall depression | −0.03 | 0.05 | 0.44 | 1, 215 | 0.51 |
| SAMS | |||||
| Baseline suicidal ideation | 0.42 | 0.04 | 87.57 | 1, 191 | <0.0001 |
| Baseline irritability | 0.08 | 0.05 | 2.27 | 1, 192 | 0.13 |
| Baseline overall depression | −0.00 | 0.02 | 0.07 | 1, 186 | 0.79 |
| Baseline-to-week-2 change in irritability | −0.12 | 0.05 | 5.22 | 1, 187 | 0.024 |
| Baseline-to-week-2 change in overall depression | −0.07 | 0.05 | 1.59 | 1, 188 | 0.21 |
β* is estimate obtained from solution of fixed effects from mixed model analyses with suicidal ideation as the dependent variable (all symptom measures were standardized with mean of 0 and standard deviation of 1). All analyses included visit, age, sex, race, and ethnicity as covariates
SE standard error, df is degrees of freedom. CO-MED Combining Medications to Enhance Depression Outcomes, EMBARC Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care, SAMS Suicide Assessment Methodology.